BidaskClub upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a strong sell rating to a sell rating in a research note released on Tuesday morning, BidAskClub reports.

Several other equities analysts also recently commented on the company. TheStreet downgraded Amphastar Pharmaceuticals from a b- rating to a c rating in a research report on Thursday, November 7th. ValuEngine raised Amphastar Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, December 3rd. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 24th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $24.05.

Amphastar Pharmaceuticals stock opened at $19.17 on Tuesday. Amphastar Pharmaceuticals has a 12 month low of $16.71 and a 12 month high of $25.43. The stock’s 50 day moving average is $19.40 and its 200-day moving average is $19.87. The company has a current ratio of 3.11, a quick ratio of 1.84 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $905.43 million, a price-to-earnings ratio of 18.26 and a beta of 1.21.

In related news, General Counsel Jason B. Shandell sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $18.44, for a total value of $461,000.00. Following the completion of the sale, the general counsel now directly owns 163,898 shares in the company, valued at $3,022,279.12. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Jason B. Shandell sold 8,205 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $19.13, for a total value of $156,961.65. Following the completion of the sale, the general counsel now owns 138,898 shares of the company’s stock, valued at $2,657,118.74. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,628 shares of company stock valued at $1,161,737. 30.80% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its stake in Amphastar Pharmaceuticals by 266.3% during the third quarter. Millennium Management LLC now owns 54,180 shares of the company’s stock worth $1,074,000 after purchasing an additional 39,389 shares during the last quarter. State of Tennessee Treasury Department lifted its stake in shares of Amphastar Pharmaceuticals by 114.1% in the 3rd quarter. State of Tennessee Treasury Department now owns 32,577 shares of the company’s stock valued at $646,000 after acquiring an additional 17,359 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Amphastar Pharmaceuticals by 7.7% in the 3rd quarter. First Trust Advisors LP now owns 124,516 shares of the company’s stock valued at $2,469,000 after acquiring an additional 8,942 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 3,731.0% in the 3rd quarter. Voya Investment Management LLC now owns 603,377 shares of the company’s stock valued at $11,965,000 after acquiring an additional 587,627 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Amphastar Pharmaceuticals by 1.3% in the 3rd quarter. Rhumbline Advisers now owns 108,931 shares of the company’s stock valued at $2,160,000 after acquiring an additional 1,358 shares during the last quarter. Hedge funds and other institutional investors own 51.23% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.